{
    "clinical_study": {
        "@rank": "152902", 
        "arm_group": [
            {
                "arm_group_label": "CJ Amlodipine/Valsartan 10/160mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Novartis Exforge 10/160mg", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are:\n\n        -  To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge\n           10/160mg after a single oral administration in healthy male volunteers\n\n        -  To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis\n           Exforge 10/160mg after a single oral administration in healthy male volunteers"
        }, 
        "brief_title": "Phase \u2160 Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Years 20-45\n\n          -  18 \u2264 BMI < 27kg/m\u00b2\n\n          -  volunteer\n\n        Exclusion Criteria:\n\n          -  Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within\n             28days prior to study medication dosing\n\n          -  Subject with symptoms of acute disease within 28days prior to study medication dosing\n\n          -  Subject with gastrointestinal diseases or surgery which might significantly change\n             absorption of medicines\n\n          -  Use of any prescription medication within 14 days prior to study medication dosing\n             and over-the-counter medication including oriental medication within 7 days prior to\n             study medication dosing\n\n          -  Subject with known for hypersensitivity reaction to amlodipine and valsartan\n\n          -  Subject with any of the following conditions in laboratory test i. AST(sGOT) or\n             ALT(sGPT) > Upper normal limit \u00d7 1.5 ii. Total bilirubin > Upper normal limit \u00d7 1.5\n             iii. eGFR< 50mL/min \u2173. continued serum potassium concentration abnormal status (on\n             baseline visit, < 3.5mEq/L or > 5.5mEq/L)\n\n          -  Positive test results for HBs Ab, HCV Ab, Syphilis regain test\n\n          -  Drug abuse or continued excessive use of caffeine (caffeine > five cups/day), severe\n             heavy smoker (cigarette > 10 cigarettes per day) and alcohol(alcohol>30g/day)\n\n          -  Subject who has been taken meal which affect on the absorption, distribution,\n             metabolism, excretion of drug, especially grapefruit juice\n\n          -  Clinically significant hypotension(SBP < 100mmHg, DBP \u226465mmHg) or hypertension(SBP\n             100mmHg, DBP < 65mmHg) when screening period\n\n          -  Participation in any clinical investigation within 60days prior to study medication\n             dosing\n\n          -  Subjects with whole blood donation within 60days, component blood donation within\n             20days and blood transfusion within 30days prior to study medication dosing\n\n          -  Subjects with decision of nonparticipation through investigator's review due to\n             laboratory test results or other excuse such as non-responding to request or\n             instruction by investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01735890", 
            "org_study_id": "CJ_AMV_102"
        }, 
        "intervention": {
            "arm_group_label": [
                "CJ Amlodipine/Valsartan 10/160mg", 
                "Novartis Exforge 10/160mg"
            ], 
            "description": "single dose", 
            "intervention_name": "CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Valsartan", 
                "Amlodipine, valsartan drug combination", 
                "Lactitol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Safety", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "September 11, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet After a Single Oral Administration in Healthy Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "pharmacokinetic parameters of amlodipine and valsartan(Maximum plasma concentration (Cmax), Area under the plasma concentration curve (AUClast))", 
            "safety_issue": "No", 
            "time_frame": "Up to 144 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01735890"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUCinf, Tmax, T1/2, CL/F", 
            "safety_issue": "No", 
            "time_frame": "up to 144 hours"
        }, 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}